Quantitative comparison of dose–effect and time–course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta‐analysis
This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo‐controlled trials that met the inclusion criteria. Pharmacodynamic models were establishe...
Saved in:
| Published in | Respirology (Carlton, Vic.) Vol. 27; no. 3; pp. 194 - 201 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chichester, UK
John Wiley & Sons, Ltd
01.03.2022
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1323-7799 1440-1843 1440-1843 |
| DOI | 10.1111/resp.14203 |
Cover
| Abstract | This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo‐controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time–course of the primary outcome (trough forced expiratory volume in the first second [FEV1]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta‐analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064–0.199) and 0.127 L (0.048–0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049–0.171), 0.127 L (0.043–0.163), 0.117 L (0.039–0.150) and 0.093 L (0.032–0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose–effect relationships. In this study, the time–course and dose–effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma‐related guidelines.
Quantitative comparison of dose‐effect and time‐course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma.
See related editorial |
|---|---|
| AbstractList | This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo-controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time-course of the primary outcome (trough forced expiratory volume in the first second [FEV
]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta-analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV
(95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064-0.199) and 0.127 L (0.048-0.163), respectively. The changes from the baseline in trough FEV
(95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049-0.171), 0.127 L (0.043-0.163), 0.117 L (0.039-0.150) and 0.093 L (0.032-0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose-effect relationships. In this study, the time-course and dose-effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma-related guidelines. This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo‐controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time–course of the primary outcome (trough forced expiratory volume in the first second [FEV 1 ]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta‐analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV 1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064–0.199) and 0.127 L (0.048–0.163), respectively. The changes from the baseline in trough FEV 1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049–0.171), 0.127 L (0.043–0.163), 0.117 L (0.039–0.150) and 0.093 L (0.032–0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose–effect relationships. In this study, the time–course and dose–effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma‐related guidelines. This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo-controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time-course of the primary outcome (trough forced expiratory volume in the first second [FEV1 ]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta-analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064-0.199) and 0.127 L (0.048-0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049-0.171), 0.127 L (0.043-0.163), 0.117 L (0.039-0.150) and 0.093 L (0.032-0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose-effect relationships. In this study, the time-course and dose-effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma-related guidelines.This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo-controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time-course of the primary outcome (trough forced expiratory volume in the first second [FEV1 ]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta-analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064-0.199) and 0.127 L (0.048-0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049-0.171), 0.127 L (0.043-0.163), 0.117 L (0.039-0.150) and 0.093 L (0.032-0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose-effect relationships. In this study, the time-course and dose-effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma-related guidelines. This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo‐controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time–course of the primary outcome (trough forced expiratory volume in the first second [FEV1]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta‐analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064–0.199) and 0.127 L (0.048–0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049–0.171), 0.127 L (0.043–0.163), 0.117 L (0.039–0.150) and 0.093 L (0.032–0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose–effect relationships. In this study, the time–course and dose–effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma‐related guidelines. Quantitative comparison of dose‐effect and time‐course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma. See related editorial This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo‐controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time–course of the primary outcome (trough forced expiratory volume in the first second [FEV1]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta‐analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064–0.199) and 0.127 L (0.048–0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049–0.171), 0.127 L (0.043–0.163), 0.117 L (0.039–0.150) and 0.093 L (0.032–0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose–effect relationships. In this study, the time–course and dose–effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma‐related guidelines. |
| Author | Zhong, Ying Li, Lujin Chen, Rui Zheng, Qingshan |
| Author_xml | – sequence: 1 givenname: Ying orcidid: 0000-0001-8919-2456 surname: Zhong fullname: Zhong, Ying organization: Shanghai University of Traditional Chinese Medicine – sequence: 2 givenname: Lujin surname: Li fullname: Li, Lujin organization: Shanghai University of Traditional Chinese Medicine – sequence: 3 givenname: Rui surname: Chen fullname: Chen, Rui organization: Shanghai University of Traditional Chinese Medicine – sequence: 4 givenname: Qingshan surname: Zheng fullname: Zheng, Qingshan email: qingshan.zheng@drugchina.net organization: Shanghai University of Traditional Chinese Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35043513$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstq3TAQhkVJaZLTbvoARdBNCDiVLN9OdyGkFwj0vjZzpBFRsCVXknM4uzxCIc_Vl8iTVLYTKKFUmxEz3z-jGc0h2bPOIiEvOTvh6bzxGIYTXuRMPCEHvChYxptC7KW7yEVW1-v1PjkM4YoxJkpWPiP7yRSi5OKA_P4ygo0mQjTXSKXrB_AmOEudpsoFvLu5Ra1RRgpW0Wj6ySPd6ANOiO7GaCQkAVI9egcRZ_Bv_-DdYJydQsZSUGO3JAPlOgwSbaRDKp9soFsTL-mAPpgQpwCEeNnDW3pKwy55-sRJ6vHa4HbO0WOEu5tfYKHbJc1z8lRDF_DFvV2RH-_Ov599yC4-vf94dnqRSVHWIsuxqlP_VVmoGqBSmEZXYck1rzZ1oyomRa6LAvJSsYaX60YqYHqTN43IE67EihwteVNvP0cMse1N6qTrwKIbQ5tXOc9LNlVZkdeP0Ks0vfTemVoXdbHmTaJe3VPjpkfVDt704Hftw0clgC2A9C4Ej7qV86c5Gz2YruWsnXahnXahnXchSY4fSR6y_hPmC7w1He7-Q7Zfz799XjR_AI71zFU |
| CitedBy_id | crossref_primary_10_1016_j_addr_2024_115459 crossref_primary_10_1111_resp_14213 crossref_primary_10_1186_s40001_024_02268_7 crossref_primary_10_1186_s12890_023_02515_3 |
| Cites_doi | 10.1002/alr.21547 10.1111/all.12480 10.1016/j.jaci.2006.01.045 10.1038/clpt.2012.69 10.1186/1471-2377-10-104 10.1136/thoraxjnl-2013-204944 10.1016/j.ejphar.2011.08.022 10.1164/rccm.201810-1868CI 10.1152/ajplung.00108.2007 10.1038/clpt.2011.242 10.1378/chest.128.3.1140 10.1016/j.rmed.2006.12.004 10.1007/s00408-017-0041-2 10.1016/j.jaip.2014.02.010 10.1111/bcp.12637 10.1016/S2213-2600(20)30389-1 10.1164/ajrccm.158.3.9707093 10.1586/eci.09.85 10.1177/0091270010390040 10.1371/journal.pmed.1003145 10.1016/j.jaci.2010.08.002 |
| ContentType | Journal Article |
| Copyright | 2022 Asian Pacific Society of Respirology. 2022 Asian Pacific Society of Respirology |
| Copyright_xml | – notice: 2022 Asian Pacific Society of Respirology. – notice: 2022 Asian Pacific Society of Respirology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
| DOI | 10.1111/resp.14203 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1440-1843 |
| EndPage | 201 |
| ExternalDocumentID | 35043513 10_1111_resp_14203 RESP14203 |
| Genre | reviewArticle Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Shanghai S&T Innovation Plan funderid: 17401970900 – fundername: National Major S&T Project funderid: 2017ZX09304003; 2018ZX09711001‐009‐011; 2018ZX09731016; 2018ZX09734005; 2018ZX10303501 – fundername: Shanghai Municipal Health Planning Commission funderid: 2018YQ48 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1OB 1OC 29P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M KBYEO KMS LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c3573-2e67435654d7aa6de2036e51f16b78d60c32f44a25d081598cda0fb28832a6dd3 |
| IEDL.DBID | DR2 |
| ISSN | 1323-7799 1440-1843 |
| IngestDate | Thu Sep 04 19:12:02 EDT 2025 Wed Aug 13 08:30:57 EDT 2025 Mon Jul 21 06:06:25 EDT 2025 Wed Oct 01 01:49:44 EDT 2025 Thu Apr 24 23:09:30 EDT 2025 Wed Jan 22 16:25:55 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | fluticasone furoate model-based meta-analysis asthma dose effect fluticasone propionate |
| Language | English |
| License | 2022 Asian Pacific Society of Respirology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3573-2e67435654d7aa6de2036e51f16b78d60c32f44a25d081598cda0fb28832a6dd3 |
| Notes | Funding information Paul Thomas Ying Zhong and Lujin Li have contributed equally to this study. National Major S&T Project, Grant/Award Numbers: 2017ZX09304003, 2018ZX09711001‐009‐011, 2018ZX09731016, 2018ZX09734005, 2018ZX10303501; Shanghai Municipal Health Planning Commission, Grant/Award Number: 2018YQ48; Shanghai S&T Innovation Plan, Grant/Award Number: 17401970900 Senior Editor Associate Editor Fanny Ko ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0001-8919-2456 |
| PMID | 35043513 |
| PQID | 2629474918 |
| PQPubID | 2045110 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2621250674 proquest_journals_2629474918 pubmed_primary_35043513 crossref_citationtrail_10_1111_resp_14203 crossref_primary_10_1111_resp_14203 wiley_primary_10_1111_resp_14203_RESP14203 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2022 2022-03-00 20220301 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: March 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | Chichester, UK |
| PublicationPlace_xml | – name: Chichester, UK – name: Australia – name: Richmond |
| PublicationTitle | Respirology (Carlton, Vic.) |
| PublicationTitleAlternate | Respirology |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Ltd – name: Wiley Subscription Services, Inc |
| References | 2021; 9 2007; 101 2010; 10 2012; 92 2015; 5 2014; 2 2007; 293 2011; 90 2019; 10 2010; 126 2005; 128 2020; 17 2014; 69 2017; 195 1998; 158 2015; 80 2006; 117 2019; 199 2010; 6 2012; 52 2011; 670 e_1_2_10_12_1 e_1_2_10_23_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_11_1 e_1_2_10_22_1 e_1_2_10_20_1 Cumpston M (e_1_2_10_10_1) 2019; 10 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 35104914 - Respirology. 2022 Mar;27(3):184-186. doi: 10.1111/resp.14213. |
| References_xml | – volume: 195 start-page: 571 year: 2017 end-page: 4 article-title: Comparative meta‐analysis of the efficacy of once‐daily fluticasone furoate 100 microG versus twice‐daily fluticasone propionate 250 microG in adolescents and adults with persistent asthma publication-title: Lung – volume: 69 start-page: 1522 year: 2014 end-page: 30 article-title: Once‐daily fluticasone furoate 50 mcg in mild‐to‐moderate asthma: a 24‐week placebo‐controlled randomized trial publication-title: Allergy – volume: 101 start-page: 378 year: 2007 end-page: 88 article-title: Summing up 100 years of asthma publication-title: Respir Med – volume: 80 start-page: 372 year: 2015 end-page: 80 article-title: Inhaled corticosteroids: potency, dose equivalence and therapeutic index publication-title: Br J Clin Pharmacol – volume: 6 start-page: 257 year: 2010 end-page: 68 article-title: Challenges of treating asthma in people who smoke publication-title: Expert Rev Clin Immunol – volume: 126 start-page: 1131 year: 2010 end-page: 8 article-title: Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma publication-title: J Allergy Clin Immunol – volume: 17 year: 2020 article-title: Health and cost impact of stepping down asthma medication for UK patients, 2001‐2017: a population‐based observational study publication-title: PLoS Med – volume: 293 start-page: L660 year: 2007 end-page: 7 article-title: Pharmacological properties of the enhanced‐affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease publication-title: Am J Physiol Lung Cell Mol Physiol – volume: 5 start-page: S7 year: 2015 end-page: 10 article-title: Epidemiology and economic burden of asthma publication-title: Int Forum Allergy Rhinol – volume: 90 start-page: 766 year: 2011 end-page: 9 article-title: Model‐based meta‐analysis for comparative efficacy and safety: application in drug development and beyond publication-title: Clin Pharmacol Ther – volume: 2 start-page: 553 year: 2014 end-page: 61 article-title: Fluticasone furoate‐vilanterol 100‐25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial publication-title: J Allergy Clin Immunol Pract – volume: 92 start-page: 352 year: 2012 end-page: 9 article-title: Longitudinal model‐based meta‐analysis in rheumatoid arthritis: an application toward model‐based drug development publication-title: Clin Pharmacol Ther – volume: 670 start-page: 244 year: 2011 end-page: 51 article-title: Long‐acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells publication-title: Eur J Pharmacol – volume: 10 start-page: 104 year: 2010 article-title: Pregabalin versus gabapentin in partial epilepsy: a meta‐analysis of dose‐response relationships publication-title: BMC Neurol – volume: 158 start-page: 827 year: 1998 end-page: 32 article-title: Comparison of serial monitoring of peak expiratory flow and FEV1 in the diagnosis of occupational asthma publication-title: Am J Respir Crit Care Med – volume: 10 year: 2019 article-title: Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of interventions publication-title: Cochrane Database Syst Rev – volume: 9 start-page: 69 year: 2021 end-page: 84 article-title: Efficacy and safety of once‐daily single‐inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double‐blind, randomised, phase 3A trial publication-title: Lancet Respir Med – volume: 117 start-page: 989 year: 2006 end-page: 94 article-title: Eosinophilic bronchitis in asthma: a model for establishing dose‐response and relative potency of inhaled corticosteroids publication-title: J Allergy Clin Immunol – volume: 128 start-page: 1140 year: 2005 end-page: 5 article-title: Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate‐to‐severe asthma publication-title: Chest – volume: 199 start-page: 1471 year: 2019 end-page: 7 article-title: Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology publication-title: Am J Respir Crit Care Med – volume: 52 start-page: 39 year: 2012 end-page: 54 article-title: Standardized visual predictive check versus visual predictive check for model evaluation publication-title: J Clin Pharmacol – volume: 69 start-page: 1056 year: 2014 end-page: 8 article-title: Changes to inhaled corticosteroid dose when initiating combination inhaler therapy in long‐acting beta agonist‐naive patients with asthma: a retrospective database analysis publication-title: Thorax – ident: e_1_2_10_2_1 doi: 10.1002/alr.21547 – ident: e_1_2_10_19_1 doi: 10.1111/all.12480 – ident: e_1_2_10_21_1 doi: 10.1016/j.jaci.2006.01.045 – ident: e_1_2_10_9_1 doi: 10.1038/clpt.2012.69 – ident: e_1_2_10_8_1 doi: 10.1186/1471-2377-10-104 – volume: 10 year: 2019 ident: e_1_2_10_10_1 article-title: Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of interventions publication-title: Cochrane Database Syst Rev – ident: e_1_2_10_14_1 doi: 10.1136/thoraxjnl-2013-204944 – ident: e_1_2_10_16_1 doi: 10.1016/j.ejphar.2011.08.022 – ident: e_1_2_10_13_1 doi: 10.1164/rccm.201810-1868CI – ident: e_1_2_10_4_1 – ident: e_1_2_10_5_1 doi: 10.1152/ajplung.00108.2007 – ident: e_1_2_10_7_1 doi: 10.1038/clpt.2011.242 – ident: e_1_2_10_23_1 doi: 10.1378/chest.128.3.1140 – ident: e_1_2_10_3_1 doi: 10.1016/j.rmed.2006.12.004 – ident: e_1_2_10_6_1 doi: 10.1007/s00408-017-0041-2 – ident: e_1_2_10_18_1 doi: 10.1016/j.jaip.2014.02.010 – ident: e_1_2_10_17_1 doi: 10.1111/bcp.12637 – ident: e_1_2_10_20_1 doi: 10.1016/S2213-2600(20)30389-1 – ident: e_1_2_10_11_1 doi: 10.1164/ajrccm.158.3.9707093 – ident: e_1_2_10_24_1 doi: 10.1586/eci.09.85 – ident: e_1_2_10_12_1 doi: 10.1177/0091270010390040 – ident: e_1_2_10_15_1 doi: 10.1371/journal.pmed.1003145 – ident: e_1_2_10_22_1 doi: 10.1016/j.jaci.2010.08.002 – reference: 35104914 - Respirology. 2022 Mar;27(3):184-186. doi: 10.1111/resp.14213. |
| SSID | ssj0003505 |
| Score | 2.3299057 |
| SecondaryResourceType | review_article |
| Snippet | This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 194 |
| SubjectTerms | Administration, Inhalation Adolescent Adult Androstadienes - therapeutic use Asthma Asthma - diagnosis Asthma - drug therapy Clinical trials dose effect Double-Blind Method Drug dosages Fluticasone Fluticasone - therapeutic use fluticasone furoate fluticasone propionate Forced Expiratory Volume Humans Meta-analysis model‐based meta‐analysis Pharmacodynamics Placebos Propionic acid Quality of Life Treatment Outcome |
| Title | Quantitative comparison of dose–effect and time–course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta‐analysis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fresp.14203 https://www.ncbi.nlm.nih.gov/pubmed/35043513 https://www.proquest.com/docview/2629474918 https://www.proquest.com/docview/2621250674 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1323-7799 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1440-1843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003505 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEF5KH4ov3i-nVlnRF4WUk73kZMWXIpYiVFQs9EXC3oLSNjk0yYtP_QmCv6t_or_EmcnltCqCvoXsZLNLZjbfzs58w9iz1ImoMuUwRdknKg_zxDjUZeMyZ4PxcyLS3n-X7R2ot4f6cI29GnNhen6IyeGGlkHrNRq4dc0lI4fd6BLsXBDVZyo1ndF-XHFHSU3xi7DbkgAhjRm4STGMZ_Xo1b_RbxDzKmKlX87uDfZ5HGwfaXK03bVu23_7hcfxf2dzk10fsCjf6ZXnFluL1W22sT-ctt9h5x86W1ESGiyJ3E8VC3ld8lA38eLsRx8Owm0VOFaphzu-xrAQFCmPyVEOD0Redqc1oFoSvHwf5rZEZyQ0fa04kYGQzIpoig_Mrw1HlzFfon8PNBMabNN-ObEv-Q5f0VHzPhWH-jiJrb04-24H2pW77GD3zafXe8lQ_iHxUi9kIiImSADgVGFhbRYinplGnZZp5hZ5yOZeilIpK3QAXKNN7oOdlw7LJwsQD_IeW69gKg8YL6NRISjAItopm0aTQ99ByKC9B4ClZuz5qAaFH7jRsUTHcTHukfD7FPR9ZuzpJLvsGUH-KLU1alMxrApNITJh1EKZNJ-xJ1Mz2DMe0tgq1h3JAOYEDAGDut9r4fQaiXRzOoXOX5Au_eX9Bdjve7ra_Bfhh-yawPwOCrLbYuvtaRcfAepq3WOyrp-UizCE |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqIhUuQPkpC6U1ggtIqTaOnY25VbTVAt0KUCv1FvkvakWbrJrk0lMfoRLPxUv0SZhxvNmWIiS4RfbEiZUZ5_N45htC3sSaOZ5yjSnKJuKZHUZSoy5LnWplpRl6Iu3JXjo-4J8OxWGIzcFcmI4fone4oWX49RoNHB3S16wctqNTMHSGXJ938IAO7XLr25w9KhE-ghH2WwmASCkDOykG8szvvfk_ugUyb2JW_9PZedBVVq09VyHGmnzfaBu9Yc5_Y3L87_k8JPcDHKWbnf4skwVXPiJLk3Dg_pj8_Nqq0uehwapITV-0kFYFtVXtri5-dBEhVJWWYqF6aDEVRoagSHHifeVwg6NFe1YBsPWC19thclP0R0LXcUk9H4iXmXNN0UD-WlP0GtMpuvhAOaFD1c3RqXpPN-mckZp22Th-jFPXqKuLSxWYV56Qg53t_Q_jKFSAiEwiRknEHOZIAObkdqRUah0emzoRF3GqR5lNhyZhBeeKCQvQRsjMWDUsNFZQZiBuk6dksYSpPCO0cJJbywGOCM1V7GQGY1uWWGEMYCw-IG9nepCbQI-OVTpO8tk2Cb9P7r_PgLzuZacdKcgfpVZn6pSHhaHOWcokH3EZZwPyqu8Gk8ZzGlW6qvUyADsBRsBLrXRq2D8mQcY5EcPg77wy_eX5OZjwF3_1_F-E18nd8f5kN9_9uPf5BbnHMN3Dx9ytksXmrHUvAYQ1es2b2i9ijDSg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5KheKLd-3Rqiv6opBystnNyYovRT3US0sVC32RsLeg2CahJ3nxqT9B8Hf5J_pLnNlcTqsi6FvITja7ZGbz7ezMNwCPYsO9SIWhFGUbicxNI2VIl5VJjXbKTgOR9s5uur0vXh_IgxV4NuTCdPwQo8ONLCOs12TgtSvOGDnuRmu0c05UnxdEitsrgkTvl-RRiQwBjLjdShBDKtWTk1Icz_LZ87-j3zDmecga_jnzy_BxGG0XavJls23Mpv36C5Hj_07nClzqwSjb6rTnKqz48hqs7fTH7dfhx7tWlyELDddEZseShawqmKsW_vTkexcPwnTpGJWpxzu2orgQEikOg6ccH_CsaI8rhLVB8Ox9nFtN3khs-lyywAYSZJZMU6ynfl0w8hmzmhx8qJrYoBfNpyP9lG2xJR8163JxQh9HvtGnJ990z7tyA_bnLz883476-g-RTeQsibinDAlEnMLNtE6dp0NTL-MiTs0sc-nUJrwQQnPpENhIlVmnp4Wh-skcxV1yE1ZLnMo6sMIr4ZxAMCKN0LFXGfbteOKktYiwxAQeD2qQ254cnWp0HObDJom-Tx6-zwQejrJ1RwnyR6mNQZvyfllY5DzlSsyEirMJPBib0aDplEaXvmqDDIJOBBE4qFudFo6vSYhvTsbY-ZOgS395f44GvBeubv-L8H1Y23sxz9--2n1zBy5yyvUIAXcbsNoct_4uIrDG3AuG9hO01zNP |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantitative+comparison+of+dose-effect+and+time-course+of+fluticasone+furoate+and+fluticasone+propionate+in+adult+and+adolescent+patients+with+persistent+asthma%3A+A+systematic+review+and+meta-analysis&rft.jtitle=Respirology+%28Carlton%2C+Vic.%29&rft.au=Zhong%2C+Ying&rft.au=Li%2C+Lujin&rft.au=Chen%2C+Rui&rft.au=Zheng%2C+Qingshan&rft.date=2022-03-01&rft.eissn=1440-1843&rft.volume=27&rft.issue=3&rft.spage=194&rft_id=info:doi/10.1111%2Fresp.14203&rft_id=info%3Apmid%2F35043513&rft.externalDocID=35043513 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-7799&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-7799&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-7799&client=summon |